

**eTable 2 Characteristics of included trials**

	Author & Year	NCT Number	P (Exp)	P (Con)	Funding Source	Mask	Region	Tumor Type	Study Design	Primary Endpoint (Outcome)	Criteria
1	Andre F 2014 <sup>12</sup>	NCT01007942	284	285	Pharmaceutical	Double	Global	BC	Super	L-PFS (+)	RECIST
2	Baselga J 2012 <sup>13</sup>	NCT00863655	485	239	Pharmaceutical	Double	Global	BC	Super	L-PFS (+)	RECIST
3	Beaver JA 2012 <sup>14</sup>										
4	Yardley DA 2013 <sup>15</sup>										
5	Piccart M 2014 <sup>16</sup>										
6	Cortes J 2011 <sup>17c</sup>	NCT00388726	508	254	Pharmaceutical	Open	Global	BC	Super	OS (+)	RECIST
7	Bergh J 2012 <sup>18</sup>	NCT00393939	296	297	Pharmaceutical	Open	Global	BC	Super	C-PFS (-)	RECIST
8	Blackwell KL 2010 <sup>19</sup>	NCT00320385	148	148	Pharmaceutical	Open	Global	BC	Super	L-PFS (+)	RECIST
9	Blackwell KL 2012 <sup>20</sup>										
10	Blay JY 2014 <sup>21</sup>	NCT00796120	61	60	Pharmaceutical	Open	Global	TRS	Super	C-PFS (-)	RECIST
11	Blumenthal GM 2012 <sup>22</sup>	NCT00428597	86	85	Pharmaceutical	Double	Global	PT	Super	L-PFS (+)	RECIST
12	Raymond E 2011 <sup>23</sup>										
13	Burger RA 2011 <sup>24</sup>	NCT00262847	625	625	Academic	Double	Global	OC	Super	L-PFS (+) <sup>d</sup>	RECIST
14	Burger RA 2013 <sup>25</sup>		623								
15	Wu YL 2014 <sup>26</sup>	NCT 01121393	242	122	Pharmaceutical	Open	IC	LC	Super	C-PFS (+)	RECIST
16	Yang JC 2015 <sup>27</sup>										
17	Miller VA 2012 <sup>28</sup>	NCT00656136	390	195	Pharmaceutical	Double	Global	LC	Super	OS (+)	RECIST
18	Gianni L 2013 <sup>29c</sup>	NCT00391092	216	208	Pharmaceutical	Open	Global	BC	Super	L-PFS (-)	RECIST
19	Motzer RJ 2013 <sup>30</sup>	NCT00678392	361	362	Pharmaceutical	Open	Global	RCC	Super	C-PFS (+)	RECIST
20	Rini BI 2011 <sup>31</sup>										
21	Elisei R 2013 <sup>32</sup>	NCT00704730	219	111	Pharmaceutical	Double	Global	TC	Super	C-PFS (+)	RECIST
22	Lynch TJ 2010 <sup>33c</sup>	NCT00112294	338	338	Pharmaceutical	Open	IC	LC	Super	C-PFS (-)	WHO
23	Long GV 2014 <sup>34</sup>	NCT 01584648	211	212	Pharmaceutical	Double	Global	M	Super	L-PFS (+)	RECIST
24	Long GV 2015 <sup>35</sup>										
25	Larkin J 2014 <sup>36</sup>	NCT 01689519	247	248	Pharmaceutical	Open	Global	M	Super	L-PFS (+)	RECIST
26	Hauschild A 2012 <sup>37</sup>	NCT 01227889	187	63	Pharmaceutical	Open	Global	M	Super	L-PFS (+)	RECIST
27	Ramalingam SS 2014 <sup>38</sup>	NCT 01360554	439	439	Pharmaceutical	Double	Global	LC	Super	C-PFS (-)	RECIST
28	Kim ES 2013 <sup>39</sup>	NCT00095199	301	304	Pharmaceutical	Open	IC	LC	Super	C-PFS (-)	WHO
			167	166							
29	Reck M 2014 <sup>40</sup>	NCT00805194	655	659	Pharmaceutical	Double	Global	LC	Super	C-PFS (+)	RECIST
30	Motzer RJ 2014 <sup>41</sup>	NCT01223027	284	286	Pharmaceutical	Open	Global	RCC	Super	C-PFS (+)	RECIST
31	Demetri GD 2013 <sup>42</sup>	NCT01271712	133	66	Pharmaceutical	Double	Global	GST	Super	C-PFS (+)	RECIST

32	Yao JC 2011 <sup>43</sup>	NCT00510068	207	203	Pharmaceutical	Double	Global	PT	Super	L-PFS (+)	RECIST
33	Pavel ME 2011 <sup>44</sup>	NCT00412061	216	213	Pharmaceutical	Double	Global	NT	Super	C-PFS (-)	RECIST
34	Escudier B 2010 <sup>45</sup>	NCT00738530	327	322	Pharmaceutical	Double	Global	RCC	Super	OS (-)	RECIST
35	Summers J 2010 <sup>46</sup>										
36	Escudier B 2NCT007 <sup>47</sup>										
37	Schwartzentruber DJ 2011 <sup>48c</sup>	NCT00019682	91	94	Academic	Single	IC	M	Super	ORR ( $\pm^a$ )	WHO
38	Shi Y 2013 <sup>49</sup>	NCT01040780	200	200	Pharmaceutical	Double	IC	LC	Non	C-PFS (+)	RECIST
39	Flaherty KT 2012 <sup>50</sup>	NCT01245062	214	108	Pharmaceutical	Open	Global	M	Super	L-PFS (+)	RECIST
40	Von Hoff DD 2013 <sup>51</sup>	NCT00844649	431	430	Pharmaceutical	Open	Global	PT	Super	OS (+)	RECIST
41	Wu YL 2013 <sup>52</sup>	NCT00883779	226	225	Pharmaceutical	Double	IC	LC	Super	L-PFS (+)	RECIST
42	Paz-Ares L 2012 <sup>53</sup>	NCT00789373	359	180	Pharmaceutical	Double	IC	LC	Super	L-PFS (+)	RECIST
43	Paz-Ares L 2013 <sup>54</sup>										
44	Sternberg CN 2010 <sup>55</sup>	NCT00334282	290	145	Pharmaceutical	Double	Global	RCC	Super	C-PFS (+)	RECIST
45	Sternberg CN 2013 <sup>56</sup>										
46	Motzer RJ 2013 <sup>57c</sup>	NCT00720941	557	553	Pharmaceutical	Open	Global	RCC	Non	C-PFS (+)	RECIST
47	Swain SM 2013 <sup>58</sup>	NCT00567190	402	406	Pharmaceutical	Double	Global	BC	Super	C-PFS (+)	RECIST
48	Baselga J 2012 <sup>59</sup>										
49	Swain SM 2015 <sup>60</sup>										
50	Swain SM 2014 <sup>61</sup>										
51	Motzer RJ 2008 <sup>62</sup>	NCT00410124	277	139	Pharmaceutical	Double	Global	RCC	Super	C-PFS (+)	RECIST
52	Motzer RJ 2010 <sup>63</sup>										
53	Kaufman PA 2015 <sup>64</sup>	NCT00337103	554	548	Pharmaceutical	Open	Global	BC	Super	C-PFS+OS (-)	RECIST
16	Sequist LV 2013 <sup>65</sup>	NCT00949650	230	115	Pharmaceutical	Open	Global	LC	Super	C-PFS (+)	RECIST
54	Yang JC 2015 <sup>27</sup>										
55	Reichardt P 2012 <sup>66c</sup>	NCT00471328	165	83	Pharmaceutical	Open	Global	GST	Super	C-PFS (-)	RECIST
56	Crown JP 2013 <sup>67</sup>	NCT00435409	221	221	Pharmaceutical	Open	Global	BC	Super	C-PFS (-)	RECIST
57	Paz-Ares LG 2012 <sup>68c</sup>	NCT00449033	452	452	Pharmaceutical	Double	Global	LC	Super	OS (-)	RECIST
58	Mackey JR 2015 <sup>69c</sup>	NCT00703326	759	385	Pharmaceutical	Double	Global	BC	Super	L-PFS (-)	RECIST
59	Morris MJ 2015 <sup>70</sup>	NCT00887198	546	542	Pharmaceutical	Double	Global	PC	Super	C-PFS+OS (+)	RECIST
60	Ryan CJ 2013 <sup>71</sup>										
61	Ryan CJ 2015 <sup>72</sup>										
62	Rini BI 2014 <sup>73</sup>	NCT00631371	400	391	Pharmaceutical	Open	Global	RCC	Super	C-PFS (-)	RECIST
63	Hutson TE 2014 <sup>74</sup>	NCT00474786	259	253	Pharmaceutical	Open	Global	RCC	Super	C-PFS (-)	RECIST
64	Iwata H 2013 <sup>75</sup>	NCT00143390	149	149	Pharmaceutical	Double	IC	BC	Non	C-TTP (-)	RECIST
65	Hecht JR 2011 <sup>76</sup>	NCT00056459	585	583	Pharmaceutical	Double	Global	CA	Super	C-PFS (+)	RECIST
66	Demetri GD 2013 <sup>77</sup>	NCT00538239	347	364	Pharmaceutical	Double	Global	S	Super	C-PFS (+)	RECIST
67	Kang YK 2013 <sup>78</sup>	NCT01151852	41	40	Academic	Double	IC	GST	Super	C-PFS (+)	RECIST
68	Motzer RJ 2013 <sup>79c</sup>	NCT01030783	260	257	Pharmaceutical	Open	Global	RCC	Super	C-PFS (+)	RECIST
69	Verma S 2012 <sup>80</sup>	NCT00829166	496	495	Pharmaceutical	Open	Global	BC	Super	C-PFS (+)	RECIST

70	Wells SA, Jr 2012 <sup>81</sup>	NCT00410761	231	100	Pharmaceutical	Double	Global	TC	Super	C-PFS (+)	RECIST
71	Socinski MA 2012 <sup>82</sup>	NCT00540514	521	531	Pharmaceutical	Open	Global	LC	Non	C-ORR (+)	RECIST
72	Chinot OL 2014 <sup>83</sup>	NCT00943826	458	463	Pharmaceutical	Double	Global	G	Super	L-PFS+OS ( $\pm^b$ )	WHO
73	Aghajanian C 2014 <sup>84</sup>	NCT00434642	242	242	Pharmaceutical	Double	IC	OC	Super	L-PFS (+)	RECIST
74	Aghajanian C 2012 <sup>85</sup>										
75	Stupp R 2014 <sup>86</sup>	NCT00689221	272	273	Pharmaceutical	Open	Global	G	Super	OS (-)	NG
76	Kudo M 2011 <sup>87c</sup>	NCT00494299	229	229	Pharmaceutical	Double	IC	HC	Super	C-TTP (-)	RECIST
77	Floquet A 2015 <sup>88</sup>	NCT00866697	472	468	Pharmaceutical	Double	Global	OC	Super	L-PFS (+)	RECIST
78	du Bois A 2014 <sup>89</sup>										
79	Colombo N 2012 <sup>90</sup>	NCT00262990	412	417	Pharmaceutical	Open	Global	OC	Super	OS (-)	RECIST
80	Monk BJ 2010 <sup>91</sup>	NCT00113607	337	335	Pharmaceutical	Open	Global	OC	Super	C-PFS (+)	RECIST
81	Monk BJ 2012 <sup>92</sup>										
82	Yao JC 2016 <sup>93</sup>	NCT01524783	205	97	Pharmaceutical	Double	Global	NT	Super	C-PFS (+)	RECIST
83	Pujade-Lauraine E 2014 <sup>94</sup>	NCT00976911	179	182	Pharmaceutical	Open	IC	OC	Super	L-PFS (+)	RECIST
84	Husain A 2016 <sup>95</sup>										
85	Brose MS 2014 <sup>96</sup>	NCT00984282	209	210	Pharmaceutical	Double	Global	TC	Super	C-PFS (+)	RECIST
86	Soria, J. C 2015 <sup>97c</sup>	NCT01523587	398	397	Pharmaceutical	Open	Global	LC	Super	C-PFS (+)	RECIST
87	Hurvitz, S. A 2015 <sup>98</sup>	NCT00876395	480	239	Pharmaceutical	Double	Global	BC	Super	L-PFS (-)	RECIST
88	Cristofanilli, M. 2016 <sup>99</sup>	NCT01942135	347	174	Pharmaceutical	Double	Global	BC	Super	L-PFS (+)	RECIST
89	Turner, N. C 2015 <sup>100</sup>										
90	Zhang, P 2017 <sup>101</sup>	NCT02253459	270	135	Pharmaceutical	Open	IC	BC	Super	C-PFS (+)	RECIST
91	Sternberg, C 2016 <sup>102</sup>	NCT01234311	832	413	Pharmaceutical	Double	Global	PC	Super	C-PFS (+)	RECIST
92	Rini, B. I 2016 <sup>103</sup>	NCT01265901	204	135	Pharmaceutical	Open	Global	RCC	Super	OS (-)	RECIST
93	Mok, T. S 2017 <sup>104</sup>	NCT02151981	279	140	Pharmaceutical	Open	Global	LC	Super	L-PFS (+)	RECIST
94	Machiels, J. P 2015 <sup>105c</sup>	NCT01345682	322	161	Pharmaceutical	Open	Global	HNC	Super	C-PFS (+)	RECIST
95	Hortobagyi, G. N 2016 <sup>106</sup>	NCT01958021	334	334	Pharmaceutical	Double	Global	BC	Super	L-PFS (+)	RECIST
96	Finn RS 2016 <sup>107</sup>	NCT01740427	444	222	Pharmaceutical	Double	Global	BC	Super	L-PFS (+)	RECIST
97	Demetri, G. D 2016 <sup>108</sup>	NCT01343277	345	173	Pharmaceutical	Open	Global	S	Super	OS (+)	RECIST
98	Choueiri, T. K 2016 <sup>109</sup>	NCT01865747	330	328	Pharmaceutical	Open	Global	RCC	Super	C-PFS (+)	RECIST
99	Blay, J. Y 2015 <sup>110c</sup>	NCT00785785	324	320	Pharmaceutical	Open	Global	GST	Super	C-PFS (-)	RECIST
100	Ryu, M. H 2015 <sup>111</sup>	NCT00915382	306	309	Academic	Open	IC	GC	Hybrid	C-PFS (+)	RECIST

Abbreviation: P, patients; Criteria, assessment criteria for tumor response or progression; NG, not given; BC, breast cancer; S, sarcoma; OC, ovarian cancer; LC, non-small-cell lung cancer; RCC, renal-cell cancer; HC, hepatocellular carcinoma; TC, thyroid cancer; M, melanoma; GST, gastrointestinal stromal tumor; NT, neuroendocrine tumor; PC, prostate cancer; G, glioblastoma; CA, colorectal adenocarcinoma; CC, cervical cancer; HNC, head & neck cancer; GC, gastric cancer; Super, superiority; Non, noninferiority; Hybrid, hybrid design, combining Superiority and noninferiority; IC, intracontinental; C-, central-assessed; L-, local-assessed; ORR, objective response rate; PFS, progression-free survival; TTP, time to progression; OS, overall survival.

<sup>a</sup>One study used objective response rate (ORR) as the primary endpoint, but we were unable to recognize which assessment (central or local assessment) for the ORR was considered as the primary endpoint (central-assessed ORR or local-assessed

ORR?). Because a significant difference was found in central review ( $p=0.03$ ) but not found in local assessment ( $p=0.05$ ), we considered the outcome of the primary endpoint as indeterminate.<sup>48</sup>

<sup>b</sup>Another study considered the local-assessed PFS and OS as coprimary endpoints: a significant difference was found in PFS ( $p<0.01$ ), but was not found in OS ( $p=0.10$ ). We considered the outcome of the primary endpoint as indeterminate as well.<sup>83</sup>

<sup>c</sup>Inconsistent conclusion (regarding significant difference) of these endpoints between two assessments.<sup>17,29,33,48,57,66,68,69,79,87</sup>

<sup>d</sup>This trial was with two arms in experimental group (Carboplatin+Paclitaxel+Bevacizumab+Placebo/Extended Bevacizumab), significant outcome was found in extended strategy when comparing with the control arm (Paclitaxel+Bevacizumab+Placebo), and we preferentially considered this trial with positive outcome for subgroup analysis.<sup>24,25</sup>